Objective
Methods
Results
Conclusions
Keywords
Introduction
- Hindricks G.
- Potpara T.
- Dagres N.
- Arbelo E.
- Bax J.J.
- Blomström-Lundqvist C.
- et al.
- Hindricks G.
- Potpara T.
- Dagres N.
- Arbelo E.
- Bax J.J.
- Blomström-Lundqvist C.
- et al.
- Saglietto A.
- Gaita F.
- Ponti R.D.
- Ferrari G.M.D.
- Anselmino M.
- Saglietto A.
- Gaita F.
- Ponti R.D.
- Ferrari G.M.D.
- Anselmino M.
- Jacobs V.
- May H.T.
- Bair T.L.
- Crandall B.G.
- Cutler M.J.
- Day J.D.
- et al.
Methods
Data Sources
Quality assurance - CHeReL.
Study Cohort
Outcomes and Covariates
Australian Bureau of Statistics (2011), “Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2011.” https://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/2033.0.55.001∼2011∼Main%20Features∼Main%20Page∼1. [accessed 1.7.21].
Statistical Analysis
Results
Baseline Characteristics
Receipt of Ablation in Follow-Up | Receipt of Early or Late Ablation | ||||||
---|---|---|---|---|---|---|---|
All | No ablation | Ablation | P-value | Early ablation | Late ablation | P-value | |
N | 46,764 | 45,350 | 1,414 | 599 | 815 | ||
Gender | <0.001 | 0.76 | |||||
Male | 24,227 (51.8%) | 23,319 (51.4%) | 907 (64.1%) | 381 (63.6%) | 526 (64.5%) | ||
Female | 22,537 (48.2%) | 22,030 (48.6%) | 507 (35.9%) | 218 (36.4%) | 289 (35.5%) | ||
Median age (Q1, Q3) | 74 (64, 82) | 74 (65, 82) | 61 (54, 68) | <0.001 | 63 (55, 69) | 60 (53, 66) | <0.001 |
<45 years | 1,729 (3.7%) | 1,593 (3.5%) | 136 (9.6%) | 53 (8.8%) | 83 (10.2%) | ||
45–64 years | 10,132 (21.7%) | 9,378 (20.7%) | 754 (53.3%) | 290 (48.4%) | 464 (56.9%) | ||
65–74 years | 12,532 (26.8%) | 12,110 (26.7%) | 422 (29.8%) | 204 (34.1%) | 218 (26.7%) | ||
>=75 years | 22,371 (47.8%) | 22,269 (49.1%) | 102 (7.2%) | 52 (8.7%) | 50 (6.1%) | ||
CHA2DS2-VASc | 2.6 (1.6) | 2.6 (1.6) | 1.3 (1.2) | <0.001 | 1.4 (1.2) | 1.2 (1.2) | 0.051 |
Cardioversion at index admission | 8,121 (17.4%) | 7,600 (16.8%) | 521 (36.8%) | <0.001 | 246 (41.1%) | 275 (33.7%) | 0.006 |
Congestive heart failure | 9,906 (21.2%) | 9,772 (21.5%) | 134 (9.5%) | <0.001 | 46 (7.7%) | 88 (10.8%) | 0.059 |
Hypertension | 19,385 (41.5%) | 19,114 (42.1%) | 271 (19.2%) | <0.001 | 108 (18.0%) | 163 (20.0%) | 0.389 |
Diabetes | 25,860 (55.3%) | 25,614 (56.5%) | 246 (17.4%) | <0.001 | 148 (24.7%) | 98 (12.0%) | <0.001 |
Stroke | 2,551 (5.5%) | 2,518 (5.6%) | 33 (2.3%) | <0.001 | 18 (3.0%) | 15 (1.8%) | 0.209 |
Myocardial infarction | 3,948 (8.4%) | 3,892 (8.6%) | 56 (4.0%) | <0.001 | 24 (4.0%) | 32 (3.9%) | 0.951 |
Coronary artery disease | 22,692 (48.5%) | 22,257 (49.1%) | 435 (30.8%) | <0.001 | 183 (30.6%) | 252 (30.9%) | 0.928 |
Major bleeding | 1,913 (4.1%) | 1,868 (4.1%) | 45 (3.2%) | 0.092 | 14 (2.3%) | 31 (3.8%) | 0.162 |
Health System Factors | |||||||
Patient type | <0.001 | <0.001 | |||||
Public patient | 25,223 (53.9%) | 24,790 (54.7%) | 433 (30.6%) | 131 (21.9%) | 302 (37.1%) | ||
Private patient | 21,383 (45.7%) | 20,404 (45.0%) | 979 (69.2%) | 468 (78.1%) | 511 (62.7%) | ||
Socioeconomic Status | <0.001 | 0.887 | |||||
Quintile 1 (lowest) | 7,483 (16.0%) | 7,365 (16.2%) | 118 (8.3%) | 51 (8.5%) | 67 (8.2%) | ||
Quintile 2 | 13,362 (28.6%) | 13,063 (28.8%) | 299 (21.1%) | 123 (20.5%) | 176 (21.6%) | ||
Quintile 3 | 7,484 (16.0%) | 7,262 (16.0%) | 222 (15.7%) | 100 (16.7%) | 122 (15.0%) | ||
Quintile 4 | 7,215 (15.4%) | 6,902 (15.2%) | 313 (22.1%) | 128 (21.4%) | 185 (22.7%) | ||
Quintile 5 (highest) | 10,139 (21.7%) | 9,693 (21.4%) | 446 (31.5%) | 188 (31.4%) | 258 (31.7%) |
Characteristics Associated With Ablation

Baseline | Baseline + Clinical | Baseline + Health System | Baseline + Clinical + Health System | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Covariate | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value |
Age | 0.95 | (0.95–0.96) | <0.001 | 0.96 | (0.95–0.96) | <0.001 | 0.95 | (0.95–0.95) | <0.001 | 0.95 | (0.95–0.95) | <0.001 |
Sex (reference – males) | 0.84 | (0.75–0.94) | 0.002 | 0.92 | (0.82–1.03) | 0.136 | 0.9 | (0.81–1.01) | 0.074 | 0.97 | (0.86–1.08) | 0.554 |
Cardioversion at index admission | 2.36 | (2.12–2.64) | <0.001 | 1.96 | (1.75–2.19) | <0.001 | ||||||
Congestive heart failure | 0.67 | (0.54–0.82) | <0.001 | 0.73 | (0.59–0.89) | 0.003 | ||||||
Hypertension | 0.74 | (0.63–0.86) | <0.001 | 0.78 | (0.66–0.91) | 0.002 | ||||||
Diabetes | 0.66 | (0.54–0.81) | <0.001 | 0.71 | (0.58–0.87) | <0.001 | ||||||
Stroke | 0.94 | (0.65–1.37) | 0.754 | 0.95 | (0.65–1.39) | 0.794 | ||||||
Myocardial infarction | 0.65 | (0.46–0.92) | 0.014 | 0.71 | (0.50–1.00) | 0.053 | ||||||
Coronary artery disease | 1.18 | (1.00–1.41) | 0.057 | 1.1 | (0.93–1.31) | 0.264 | ||||||
Major bleeding | 1.14 | (0.85–1.54) | 0.386 | 1.09 | (0.81–1.47) | 0.562 | ||||||
Year of index admission | 1.08 | (1.05–1.10) | <0.001 | 1.07 | (1.05–1.10) | <0.001 | ||||||
Private patient | 2.84 | (2.53–3.19) | <0.001 | 2.65 | (2.35–2.97) | <0.001 | ||||||
Socioeconomic status | 1.21 | (1.16–1.25) | <0.001 | 1.18 | (1.13–1.22) | <0.001 | ||||||
Concordance Index | 0.75 (0.02) | 0.76 (0.02) | 0.79 (0.02) | 0.80 (0.02) |
Characteristics Associated With Early Ablation
Baseline | Baseline + Clinical | Baseline + Health System | Baseline + Clinical + Health System | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Covariate | OR | 95% CI | P-value | OR | 95% CI | P-value | OR | 95% CI | P-value | OR | 95% CI | P-value |
Age | 1 | (0.99–1.00) | <0.001 | 1 | (0.99–1.00) | 0.001 | 1.02 | (1.01–1.03) | 0.004 | 1.02 | (1.01–1.03) | 0.002 |
Sex | 0.98 | (0.79–1.23) | 0.885 | 0.98 | (0.78–1.23) | 0.862 | 1.03 | (0.82–1.30) | 0.786 | 1.02 | (0.80–1.29) | 0.889 |
Cardioversion at index admission | 1.27 | (1.02–1.58) | 0.034 | 1.25 | (1.00–1.57) | 0.05 | ||||||
Congestive heart failure | 0.72 | (0.47–1.10) | 0.129 | 0.77 | (0.50–1.19) | 0.24 | ||||||
Hypertension | 0.87 | (0.63–1.20) | 0.385 | 0.81 | (0.58–1.13) | 0.212 | ||||||
Diabetes | 1.65 | (1.10–2.47) | 0.015 | 1.6 | (1.06–2.41) | 0.025 | ||||||
Stroke | 1.36 | (0.64–2.92) | 0.426 | 1.33 | (0.61–2.89) | 0.473 | ||||||
Myocardial infarction | 1 | (0.48–2.05) | 0.989 | 0.96 | (0.46–2.00) | 0.919 | ||||||
Coronary artery disease | 0.82 | (0.58–1.17) | 0.273 | 0.77 | (0.53–1.10) | 0.146 | ||||||
Major bleeding | 0.56 | (0.29–1.06) | 0.076 | 0.54 | (0.28–1.03) | 0.062 | ||||||
Year of index admission | 1 | (1.00–1.00) | <0.001 | 1 | (1.00–1.00) | <0.001 | ||||||
Private patient | 2.06 | (1.61–2.64) | <0.001 | 2.04 | (1.59–2.61) | <0.001 | ||||||
Socioeconomic status | 0.96 | (0.89–1.04) | 0.291 | 0.96 | (0.88–1.04) | 0.292 | ||||||
AUC | 0.43 (0.06) | 0.53 (0.04) | 0.60 (0.04) | 0.60 (0.04) |
Discussion
Main Findings
- Jacobs V.
- May H.T.
- Bair T.L.
- Crandall B.G.
- Cutler M.J.
- Day J.D.
- et al.
Impact of Health System Factors on Receiving Ablation
Limitations
Conclusion
Competing Interests
Funding
Author Contributions
Acknowledgements
Supplementary Data
- Supplementary Material
References
- Increasing trends in hospitalisations due to atrial fibrillation in Australia from 1993 to 2013.Heart. 2019; 105: 1358-1363https://doi.org/10.1136/heartjnl-2018-314471
- Estimating the current and future prevalence of atrial fibrillation in the Australian adult population.Med J Aust. 2015; 202: 32-35https://doi.org/10.5694/mja14.00238
- National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018.Heart Lung Circ. 2018; 27: 1209-1266https://doi.org/10.1016/j.hlc.2018.06.1043
- Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016.Heart. 2019; 105: 27-33https://doi.org/10.1136/heartjnl-2018-312977
- Epidemiology of Atrial Fibrillation: The Australian and Asia-Pacific Perspective.Heart Lung Circ. 2017; 26: 870-879https://doi.org/10.1016/j.hlc.2017.05.120
- Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century.Int J Cardiol. 2013; 167: 1807-1824https://doi.org/10.1016/j.ijcard.2012.12.093
- 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study.Lancet. 2015; 386: 154-162https://doi.org/10.1016/S0140-6736(14)61774-8
- Catheter Ablation for Atrial Fibrillation in 2019.JAMA. 2019; 322: 686-687https://doi.org/10.1001/jama.2019.10929
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.Eur Heart J. 2021; 42: 373-498https://doi.org/10.1093/eurheartj/ehaa612
- Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).J Am Heart Assoc. 2015; 4: e001901https://doi.org/10.1161/JAHA.115.001901
- Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.JAMA. 2019; 321: 1261-1274https://doi.org/10.1001/jama.2019.0693
- Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.JAMA. 2019; 321: 1275-1285https://doi.org/10.1001/jama.2019.0692
- Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997–2016.Intern Med J. 2018; 48: 427-432https://doi.org/10.1111/imj.13706
- Catheter Ablation vs. Anti-Arrhythmic Drugs as First-Line Treatment in Symptomatic Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Front Cardiovasc Med. 2021; 8664647https://doi.org/10.3389/fcvm.2021.664647
- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.N Engl J Med. 2021; 384: 305-315
- A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale.Am Heart J. Dec. 2018; 206: 94-104https://doi.org/10.1016/j.ahj.2018.05.020
- Trends and predictors of early ablation for Atrial Fibrillation in a Nationwide population under age 65: a retrospective observational study.BMC Cardiovasc Disord. 2020; 20: 161https://doi.org/10.1186/s12872-020-01446-9
- Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.Eur Heart J. 2016; 37: 2478-2487https://doi.org/10.1093/eurheartj/ehw087
- The Impact of Repeated Cardioversions for Atrial Fibrillation on Stroke, Hospitalizations, and Catheter Ablation Outcomes.J Atr Fibrillation. 2019; 11https://doi.org/10.4022/jafib.2164
- Quality assurance - CHeReL.https://www.cherel.org.au/quality-assuranceDate accessed: July 30, 2021
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation.Chest. 2010; 137: 263-272https://doi.org/10.1378/chest.09-1584
Australian Bureau of Statistics (2011), “Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2011.” https://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/2033.0.55.001∼2011∼Main%20Features∼Main%20Page∼1. [accessed 1.7.21].
- Utilization Rates of Pancreatectomy, Radical Prostatectomy, and Nephrectomy in New York, Ontario, and New South Wales, 2011 to 2018.JAMA Netw Open. 2021; 4: e215477https://doi.org/10.1001/jamanetworkopen.2021.5477
- Systematic review of discharge coding accuracy.J Public Health (Oxf). 2012; 34: 138-148https://doi.org/10.1093/pubmed/fdr054.1
- The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients.Am. J. Epidemiol. Feb. 2013; 177 (doi: 10/f4pdjs): 292-298
Article info
Publication history
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Catheter Ablation for Atrial Fibrillation: Are We Isolating Our Most Vulnerable Patients?Heart, Lung and CirculationVol. 31Issue 10
- PreviewA central tenant of the health care system in Australia, which is based on a hybrid public-private model underpinned by the mandatory public insurance scheme of Medicare, is equitable access and affordable health care for all [1]. Medicare provides universal basic health care coverage to citizens, permanent residents, and refugees. Over and above this, private health insurance offers the opportunity to individuals to expand their health care coverage including the ability to choose their treating physicians, location of care and faster access to care in the form of shorter waiting lists through private hospitals.
- Full-Text
- Preview